ELLIPSS: ELucidating the Landscape of Immunoendotypes in Psoriatic Skin and Synovium

ELLIPSS：阐明银屑病皮肤和滑膜的免疫内型概况

• 批准号: 10451910
• 负责人: Johann Eli Gudjonsson
• 金额: $ 110万
• 依托单位: UNIVERSITY OF ROCHESTER
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-03-21 至 2026-12-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10451910
• 关键词: Advertising; Affect; Aftercare; Autoimmune; Award; Bioinformatics; Biopsy; Blood; Cell Communication; Cells; Chronic small plaque psoriasis; Clinical Data; Clinical Protocols; Cohort Studies; Collaborations; Collection; Common Data Element; Communication; Consult; Coupled; Cues; Data; Data Collection; Dermatologist; Development; Disease; Disease Pathway; Elderly; Electronic Health Record; Enrollment; Exclusion Criteria; Fostering; Funding Opportunities; Genetic; Goals; Human Resources; Immune; Immunologics; Immunologist; Immunology; Individual; Inflammation; Joints; Knowledge; Knowledge Portal; Leadership; Link; Lupus; Manuscripts; Measures; Mediating; Medicine; Michigan; Molecular; Molecular Analysis; Molecular Profiling; Participant; Pathogenicity; Pathologist; Pathology; Patient Recruitments; Patient-Focused Outcomes; Patients; Personnel Management; Phenotype; Physicians; Pilot Projects; Proteomics; Protocols documentation; Psoriasis; Psoriatic Arthritis; Quality Control; Research Personnel; Resolution; Rheumatoid Arthritis; Sampling; Science; Scientist; Site; Skin; Standardization; Structure; Synovial Membrane; Systemic Lupus Erythematosus; Systems Biology; Technology; Testing; Tissue Banks; Tissue Sample; Tissues; Training; United States; Universities; Work; biomarker identification; cell type; chronic pain; clinical phenotype; clinically relevant; cohort; data sharing; disease phenotype; ethnic diversity; gut microbiome; improved outcome; joint inflammation; joint injury; lipidomics; loss of function; microbial; microbiome; multidisciplinary; multiple omics; new therapeutic target; oral microbiome; participant enrollment; phenotypic data; programs; racial and ethnic; recruit; repository; rheumatologist; sample collection; scale up; skin microbiome; statistics; success; synergism; tissue processing; transcriptomics; treatment response

ABSTRACT Psoriatic Spectrum Diseases (PSD) affect over 8 million individuals in the U.S. living with psoriasis (PsO) or psoriatic arthritis (PsA) and encompass heterogeneous phenotypes of disease, ranging from plaque, guttate, palmoplantar, inverse, pustular, and erythrodermic forms of psoriasis, to synovial, enthesial, and axial forms of PsA. Here, we assembled a world class multidisciplinary team of scientists in PSD cohort assembly, clinical phenotyping, biosample acquisition, pathology, statistics, and bioinformatics, for the Accelerating Medicines Partnership Autoimmune and Immune-Mediated Diseases (AMP AIM) PSD Disease Teams (DTs). The major scientific goals of the PSD DT are to understand the cellular and molecular composition of distinct PSD endotypes and how they link with phenotypes, to identify how key pathogenic or regulatory cells spatially interact with each other and with environmental cues (i.e., microbiome), and to define at a single-cell level how the transition to PsA unfolds in the setting of PsO. To accomplish the goals of the PSD AMP, we propose the creation of the ELLIPSS (ELucidating the Landscape of Immunoendotypes in Psoriatic Skin and Synovium) Disease Team (DT). The AIMS of the ELLIPSS Team are to 1) to enroll diverse PSD cohorts and perform clinical phenotyping, data capture, and tissue collection. 2) to implement an effective management plan for the ELLIPSS multidisciplinary team. 3) to optimize interface of ELLIPSS team with AMP-AIM network. Lastly, a robust Opportunities Fund (OF) management program is proposed under the direction and leadership of Dr. James T. Elder at University of Michigan. The ELLIPSS PSD DT will efficiently integrate with the AMP AIM Network, facilitate collection of PSD biosamples, and help provide an unprecedented view of cell types and states, along with spatial and tissue interactions (skin, joint, blood, microbiome) to deconstruct/reconstruct the psoriatic disease spectrum.

摘要 银屑病谱系疾病（PSD）影响美国超过800万患有银屑病（PsO）或银屑病性关节炎的个体。 银屑病性关节炎（PsA）并包括疾病的异质表型，从斑块，滴状， 掌跖型、反型、脓疱型和红皮病型银屑病，至滑膜型、附着点型和轴型银屑病， PsA。在这里，我们组建了一个世界级的多学科科学家团队，在PSD队列组装，临床 表型分析、生物样本采集、病理学、统计学和生物信息学，用于加速药物 自身免疫和免疫介导的疾病伙伴关系（AMP AIM）PSD疾病团队（DT）。 PSD DT的主要科学目标是了解不同细胞的细胞和分子组成， PSD内型以及它们如何与表型联系，以确定关键的致病或调节细胞在空间上 彼此交互并与环境线索交互（即，微生物组），并在单细胞水平上定义如何 向PsA的转变在PsO的背景下展开。为了实现PSD AMP的目标，我们提出 创建ELLIPSS（阐明银屑病皮肤和滑膜中的免疫内型景观） 疾病团队（DT）。ELLIPSS团队的目标是：1）招募不同的PSD队列，并进行临床研究 表型分析、数据采集和组织收集。2)为ELLIPSS实施有效的管理计划 多学科团队。3)优化ELLIPSS团队与AMP-AIM网络的接口。最后，一个强大的 机会基金（OF）管理计划的指导和领导下提出的博士詹姆斯T。 密歇根大学的长老。 ELLIPSS PSD DT将有效地与AMP AIM网络集成，便于PSD生物样品的收集， 并有助于提供细胞类型和状态的前所未有的视图，沿着空间和组织相互作用（皮肤， 关节、血液、微生物组）来解构/重建银肩病疾病谱。